

# Matteo Ziacchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8912630/publications.pdf>

Version: 2024-02-01

83  
papers

1,219  
citations

393982

19  
h-index

476904

29  
g-index

83  
all docs

83  
docs citations

83  
times ranked

1366  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phrenic Stimulation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 402-410.	2.1	114
2	From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. <i>Expert Review of Medical Devices</i> , 2013, 10, 551-573.	1.4	78
3	Meta-analysis of randomized controlled trials evaluating left ventricular vs. biventricular pacing in heart failure: effect on all-cause mortality and hospitalizations. <i>European Journal of Heart Failure</i> , 2012, 14, 652-660.	2.9	45
4	Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 194-205.	3.3	45
5	Predictors of long-term survival free from relapses after extraction of infected CIED. <i>Europace</i> , 2018, 20, 1018-1027.	0.7	43
6	Implantable cardioverter-defibrillator programming and electrical storm: Results of the OBSERVational registry On long-term outcome of ICD patients (OBSERVO-ICD). <i>Heart Rhythm</i> , 2016, 13, 1987-1992.	0.3	38
7	Multiparametric Implantable Cardioverter-Defibrillator Algorithm for Heart Failure Risk Stratification and Management: An Analysis in Clinical Practice. <i>Circulation: Heart Failure</i> , 2021, 14, e008134.	1.6	29
8	Left ventricular lead stabilization to retain cardiac resynchronization therapy at long term: when is it advisable?. <i>Europace</i> , 2014, 16, 533-540.	0.7	28
9	Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. <i>Europace</i> , 2020, 22, 1855-1863.	0.7	28
10	Long-term complications in patients implanted with subcutaneous implantable cardioverter-defibrillators: Real-world data from the extended ELISIR experience. <i>Heart Rhythm</i> , 2021, 18, 2050-2058.	0.3	28
11	Prevention of infections in cardiovascular implantable electronic devices beyond the antibiotic agent. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 554-564.	0.6	27
12	Subcutaneous implantable cardioverter defibrillator eligibility according to a novel automated screening tool and agreement with the standard manual electrocardiographic morphology tool. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 52, 61-67.	0.6	27
13	Cardiac resynchronization therapy and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD). <i>Europace</i> , 2018, 20, 979-985.	0.7	26
14	Physical Activity Measured by Implanted Devices Predicts Atrial Arrhythmias and Patient Outcome: Results of IMPLANTED (Italian Multicentre Observational Registry on Patients With Implantable) <i>TJ ETQq0 0 0 rgBT 10verlock 24 Tf 50 2</i>	0.7	24
15	Impact on All-Cause and Cardiovascular Mortality of Cardiac Implantable Electronic Device Complications. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 382-392.	1.3	24
16	New left ventricular active fixation lead: The experience of lead extraction. <i>Indian Heart Journal</i> , 2015, 67, S97-S99.	0.2	22
17	Clinically oriented device programming in bradycardia patients: part 1 (sinus node disease). Proposals from AIAC (Italian Association of Arrhythmology and Cardiac Pacing). <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 161-169.	0.6	22
18	Battery drain in daily practice and medium-term projections on longevity of cardioverter-defibrillators: an analysis from a remote monitoring database. <i>Europace</i> , 2016, 18, 1366-1373.	0.7	21

#	ARTICLE	IF	CITATIONS
19	Effect of PR interval and pacing mode on persistent atrial fibrillation incidence in dual chamber pacemaker patients: a sub-study of the international randomized MINERVA trial. <i>Europace</i> , 2019, 21, 636-644.	0.7	20
20	Cardiac resynchronization therapy and cardiac sympathetic function. <i>European Journal of Clinical Investigation</i> , 2015, 45, 792-799.	1.7	18
21	Cardiac resynchronization therapy: How did consensus guidelines from Europe and the United States evolve in the last 15 years?. <i>International Journal of Cardiology</i> , 2018, 261, 119-129.	0.8	18
22	Clinically oriented device programming in bradycardia patients: part 2 (atrioventricular blocks and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	17
23	Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes. <i>Nucleus</i> , 2018, 9, 442-459.	0.6	17
24	Rate and impact on patient outcome and healthcare utilization of complications requiring surgical revision: Subcutaneous versus transvenous implantable defibrillator therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1712-1723.	0.8	17
25	Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1835-1842.	0.8	17
26	Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICD. <i>Indian Heart Journal</i> , 2015, 67, 56-59.	0.2	16
27	Leadless left ventricular endocardial pacing: a real alternative or a luxury for a few?. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 530-533.	0.7	16
28	Role of drugs and devices in patients at risk of sudden cardiac death. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 575-594.	1.0	15
29	The role of atrial sensing for new-onset atrial arrhythmias diagnosis and management in single-chamber implantable cardioverter-defibrillator recipients: Results from the THINGS registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 846-853.	0.8	15
30	Holter ECG for pacemaker/defibrillator carriers: what is its role in the era of remote monitoring?. <i>Heart</i> , 2015, 101, 1272-1278.	1.2	14
31	Electrocardiographic Eligibility for Subcutaneous Implantable Cardioverter Defibrillator: Evaluation during Bicycle Exercise. <i>Heart Lung and Circulation</i> , 2016, 25, 476-483.	0.2	14
32	Subcutaneous implantable cardioverter-defibrillator and defibrillation testing: A propensity-matched pilot study. <i>Heart Rhythm</i> , 2021, 18, 2072-2079.	0.3	14
33	Successful defibrillation verification in subcutaneous implantable cardioverter-defibrillator recipients by low-energy shocks. <i>Clinical Cardiology</i> , 2019, 42, 612-617.	0.7	13
34	Serratus anterior plane block in subcutaneous implantable cardioverter defibrillator implantation: A case-control analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 144-149.	0.8	13
35	Outcomes with Dronedaronone in Atrial Fibrillation: What Differences Between Real-World Practice and Trials? A Meta-Analysis and Meta-Regression Analysis. <i>Current Pharmaceutical Design</i> , 2017, 23, 944-951.	0.9	13
36	Effect of fixed-rate vs. rate-RESPONSive pacing on exercise capacity in patients with permanent, refractory atrial fibrillation and left ventricular dysfunction treated with atrioventricular junction ablation and biventricular pacing (RESPONSIBLE): a prospective, multicentre, randomized, single-blind study. <i>Europace</i> , 2017, 19, euw035.	0.7	12

#	ARTICLE	IF	CITATIONS
37	Less is more: Can we achieve cardiac resynchronization with 2 leads only?. <i>International Journal of Cardiology</i> , 2017, 249, 184-190.	0.8	12
38	Cardiac Resynchronization Therapy. <i>Heart Failure Clinics</i> , 2017, 13, 117-137.	1.0	12
39	Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 263.	1.2	12
40	Clinical and organizational management of cardiac implantable electronic device replacements. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 531-541.	0.6	12
41	Bipolar active fixation left ventricular lead or quadripolar passive fixation lead? An Italian multicenter experience. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 192-200.	0.6	12
42	Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. <i>Heart</i> , 2022, 108, 54-60.	1.2	12
43	Implantable cardioverter defibrillators and devices for cardiac resynchronization therapy: what perspective for patientsâ€™ apps combined with remote monitoring?. <i>Expert Review of Medical Devices</i> , 2022, 19, 155-160.	1.4	12
44	Reduction of admissions for urgent and elective pacemaker implant during the COVID-19 outbreak in Northern Italy. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 22-27.	0.6	11
45	Clinical impact of defibrillation testing in a real-world ICD population: Data from the ELISIR registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 468-476.	0.8	10
46	Is 40 Joules Enough to Successfully Defibrillate With Subcutaneous Implantable Cardioverter-Defibrillators?. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 767-776.	1.3	10
47	Long-term progression of rhythm and conduction disturbances in pacemaker recipients: findings from the Pacemaker Expert Programming study. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 357-365.	0.6	9
48	The Impact of COVID-19 Pandemic and Lockdown Restrictions on Cardiac Implantable Device Recipients with Remote Monitoring. <i>Journal of Clinical Medicine</i> , 2021, 10, 5626.	1.0	9
49	Left Ventricular Reverse Remodeling Elicited by a Quadripolar Lead: Results from the Multicenter Per4mer Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 250-260.	0.5	8
50	Can we predict new AF occurrence in single-chamber ICD patients? Insights from an observational investigation. <i>International Journal of Cardiology</i> , 2017, 230, 275-280.	0.8	8
51	Rate-responsive pacing and atrial high rate episodes in cardiac resynchronization therapy patients: Is low heart rate the key?. <i>Clinical Cardiology</i> , 2019, 42, 820-828.	0.7	8
52	Time to therapy delivery and effectiveness of the subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2019, 16, 1531-1537.	0.3	8
53	Effects of cardiac resynchronization therapy on right ventricular function during rest and exercise, as assessed by radionuclide angiography, and on NT-proBNP levels. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 123-132.	1.4	8
54	Risk of syncopal recurrences in patients treated with permanent pacing for bradyarrhythmic syncope: role of correlation between symptoms and electrocardiogram findings. <i>Europace</i> , 2020, 22, 1729-1736.	0.7	8

#	ARTICLE	IF	CITATIONS
55	Acute shock efficacy of the subcutaneous implantable cardioverter-defibrillator according to the implantation technique. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1695-1703.	0.8	8
56	Causes of syncopal recurrences in patients treated with permanent pacing for bradyarrhythmic syncope: Findings from the SYNCOPACED registry. <i>Heart Rhythm</i> , 2021, 18, 770-777.	0.3	8
57	Clinically guided pacemaker choice and setting: pacemaker expert programming study. <i>Europace</i> , 2016, 19, euw256.	0.7	7
58	Atrial fibrillation and prediction of mortality by conventional clinical score systems according to the setting of care. <i>International Journal of Cardiology</i> , 2018, 261, 73-77.	0.8	7
59	External implantable defibrillator as a bridge to reimplant after explant for infection: Experience from two centers. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 532-535.	0.5	6
60	Intraoperative PRAETORIAN score for early assessment of S-ICD implantation: A proof-of-concept study. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 3035-3041.	0.8	6
61	Shoulder Function After Cardioverter-Defibrillator Implantation: 5-Year Follow-up. <i>Annals of Thoracic Surgery</i> , 2020, 110, 608-614.	0.7	5
62	Implantable Cardioverter Defibrillator Multisensor Monitoring during Home Confinement Caused by the COVID-19 Pandemic. <i>Biology</i> , 2022, 11, 120.	1.3	5
63	The need for a subsequent transvenous system in patients implanted with subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2022, 19, 1958-1964.	0.3	5
64	Cardiac Resynchronization Therapy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 673-693.	0.7	4
65	Predictors of nonsimultaneous interventricular delay at cardiac resynchronization therapy optimization. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 299-305.	0.6	4
66	Lead choice in cardiac implantable electronic devices: an Italian survey promoted by AIAC (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	1.4	4
67	Driving restriction in patients with cardiac implantable electronic devices: an overview of worldwide regulations. <i>Expert Review of Medical Devices</i> , 2020, 17, 297-308.	1.4	4
68	Wireless Endocardial Atrial (and Ventricular) Sensing with no Implanted Power Source: a Proposal. <i>Journal of Medical Systems</i> , 2019, 43, 159.	2.2	3
69	Temporal patterns of premature atrial complexes predict atrial fibrillation occurrence in bradycardia patients continuously monitored through pacemaker diagnostics. <i>Internal and Emergency Medicine</i> , 2020, 15, 599-606.	1.0	3
70	Preoperative checklist to reduce the risk of cardiac implantable electronic device infections. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, 45, 262-269.	0.5	3
71	Management of patients explanted for implantable cardioverter defibrillator infections: Bridge therapy with external temporary ICD. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1884-1889.	0.5	2
72	The Practice of Deep Sedation in Electrophysiology and Cardiac Pacing Laboratories: Results of an Italian Survey Promoted by the AIAC (Italian Association of Arrhythmology and Cardiac Pacing). <i>Journal of Clinical Medicine</i> , 2021, 10, 5035.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Vascular Accesses in Cardiac Stimulation and Electrophysiology: An Italian Survey Promoted by AIAC (Italian Association of Arrhythmias and Cardiac Pacing). <i>Biology</i> , 2022, 11, 265.	1.3	2
74	Usefulness of the MAGGIC Score in Predicting the Competing Risk of Non-Sudden Death in Heart Failure Patients Receiving an Implantable Cardioverter-Defibrillator: A Sub-Analysis of the OBSERVO-ICD Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 121.	1.0	2
75	Against all odds: Targeted pacing site for resynchronization therapy by venoplasty and active fixation lead. <i>Indian Heart Journal</i> , 2015, 67, 574-576.	0.2	0
76	Oral loading of propafenone: restoring its role before restoring rhythm. <i>Europace</i> , 2017, 19, 1903-1903.	0.7	0
77	Cost-effectiveness of cardiac resynchronization therapy. <i>Journal of Medical Economics</i> , 2020, 23, 1375-1378.	1.0	0
78	A Historical Perspective of Cardiac Implantable Electronic Device Infection: How a Menace Can Drive Technological and Clinical Improvement. <i>Hearts</i> , 2021, 2, 202-212.	0.4	0
79	Prevention of Infection: Indications, Device Programming, Patient Follow-Up. , 2020, , 209-229.		0
80	Atrial Fibrillation in Patients with Cardiac Resynchronization Therapy: Clinical Management and Outcome. <i>Journal of Atrial Fibrillation</i> , 2013, 5, 748.	0.5	0
81	The "Defibrillation Testing, Why Not?"-survey. Testing of subcutaneous and transvenous defibrillators in the Italian clinical practice. <i>IJC Heart and Vasculature</i> , 2022, 38, 100952.	0.6	0
82	Combined Use of S-ICD and Absorbable Antibacterial Envelopes: A Proof-of-concept Study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, , 1.	0.6	0
83	Long-term follow-up of patients with a quadripolar active fixation left ventricular lead. An Italian multicenter experience. <i>Journal of Cardiovascular Electrophysiology</i> , 0, , .	0.8	0